People's Justice

Case guide

Gabapentin for an off-label use: questions to ask

Off-label means a use outside the drug's approved label. Ask why gabapentin was chosen and what risks and other options fit your condition.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202610 sources

This may apply to you if

  • Identify the actual medicine and the dates in your pharmacy records.
  • Describe the diagnosis or symptoms actually recorded by your health team.
  • Ask what evidence would link the medicine to your condition.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

Sheng-En Tsai · Institute of Medicine, Chung Shan Medical University; Changhua Christian Hospital · First-listed study author

Finding: The 2024 author abstract reports no substantial increase in dementia risk among the chronic-pain patients studied. This differs from the 2025 population and does not prove all use safe.

Tsai et al., gabapentin and dementia in chronic pain, 2024 (opens in a new tab) · May 9, 2024 · Checked Oct 3, 2026

The evidence and its limits

Case Western Reserve University School of Medicine; Arizona State University · Regional Anesthesia & Pain Medicine · 2025

Gabapentin prescriptions and dementia in chronic low back pain

Design:
Cohort
Participants:
26,416 adults following matching as reported in the author abstract; no assumed per-arm or doubled count
Finding:
Higher recorded dementia and mild impairment incidence in certain prescription groups.
Main limitation
Retrospective records and selected back-pain population; association is not individual cause. Prescriptions do not confirm dose consumption. Full paper not reviewed.

Read the source: Gabapentin prescriptions and dementia in chronic low back pain (opens in a new tab) · Checked Oct 3, 2026

Chung Shan Medical University; Changhua Christian Hospital · Journal of Affective Disorders · 2024

Gabapentin and dementia in chronic-pain patients

Design:
Case-control
Participants:
Underlying cohort of 201,492 chronic-pain patients aged 50 or older; final matched comparison count not specified in the author abstract
Finding:
No substantial increased dementia risk in the adjusted analysis described by the abstract.
Main limitation
Nested case-control study in a different population; not proof of safety for every person. Underlying cohort is not a verified matched sample count. Full paper not reviewed.

Read the source: Gabapentin and dementia in chronic-pain patients (opens in a new tab) · Checked Oct 3, 2026

The short answer

What does off-label prescribing mean?
It means using an approved drug outside its approved use. That can involve a different condition, dose or way of giving the medicine. [10]
What should I ask the prescriber about the choice?
Ask which condition the drug is meant to treat and how benefit will be checked. Ask about risks and approved alternatives for that condition. [10]
What does the memory research establish?
The studies found different results in groups of pain patients. They do not show what caused one person’s harm. [1]
How does the old marketing case differ from my care?
The May 2004 DOJ notice concerns how Neurontin was sold. It does not announce a current payout plan for people with dementia. [5]

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

What does off-label prescribing mean?

It means using an approved drug outside its approved use. That can involve a different condition, dose or way of giving the medicine.

FDA says clinicians generally may do this when they judge it medically appropriate. FDA has not determined that the drug is safe and effective for that unapproved use. Ask what evidence supports the proposed use for you.

What should I ask the prescriber about the choice?

Ask which condition the drug is meant to treat and how benefit will be checked. Ask about risks and approved alternatives for that condition.

The FDA patient guide suggests discussing scientific support, possible benefits and harms, and insurance coverage. Those are questions for the clinician; the term off-label alone is not a reason to choose or reject a medicine yourself.

What does the memory research establish?

The studies found different results in groups of pain patients. They do not show what caused one person’s harm.

The 2025 back-pain study found an association with dementia diagnoses in some prescription groups. The 2024 Taiwan analysis found no substantial rise in adjusted risk. Neither study turns a prescription count into a personal treatment or claim rule.

How does the old marketing case differ from my care?

The May 2004 DOJ notice concerns how Neurontin was sold. It does not announce a current payout plan for people with dementia.

The notice describes Warner-Lambert's agreement to plead guilty and resolve criminal and civil liabilities. Historical company promotion and an individual clinician's care decision are separate questions. Ask a lawyer which actual conduct and records matter to the claim you want assessed.

What care and prescription records should I save?

Keep the reason for treatment, exact drug and dose dates. Ask the provider for missing care records and mark uncertain details.

Do not change the dose on your own to match a research group. Use the drug as directed and discuss changes with the prescriber. Covered health-record access includes exceptions; ask what authorization is needed for help obtaining copies.

What should I confirm before legal work starts?

Ask what harm, law and filing limit need a check. Get the lawyer's fee and expense terms in writing before agreeing.

The model fee rule calls for an explanation of percentages and expenses in a fee tied to recovery. It is not a statement of this provider's actual terms. Ask what costs may be owed after a loss and which work is covered.

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Sources

  1. Eghrari et al., gabapentin prescriptions and dementia in chronic low back pain, 2025Eghrari et al., gabapentin prescriptions and dementia in chronic low back pain, 2025 · study
  2. Tsai et al., gabapentin and dementia in chronic pain, 2024Tsai et al., gabapentin and dementia in chronic pain, 2024 · study
  3. MedlinePlus gabapentin drug informationMedlinePlus gabapentin drug information · regulator
  4. NIA memory problems, forgetfulness and agingNIA memory problems, forgetfulness and aging · regulator
  5. DOJ Warner-Lambert off-label promotion resolution, May13,2004DOJ Warner-Lambert off-label promotion resolution, May13,2004 · regulator
  6. ABA Model Rule 1.5: FeesABA Model Rule 1.5: Fees
  7. HHS your medical recordsHHS your medical records · regulator
  8. SDNY filing time-limit FAQSDNY filing time-limit FAQ · court
  9. U.S. Courts civil case processU.S. Courts civil case process · court
  10. FDA explanation of off-label use

Checked against 10 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026